Related Experiment Videos
A platelet activating factor receptor antagonist prevents the development of chronic arthritis in mice
I Palacios1, R Miguélez, O Sánchez-Pernaute
1Inflammation Research Laboratory, Rheumatology Division, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.
Objective:
To examine the effect of treatment with the platelet activating factor (PAF) receptor antagonist BN 50730 on the clinical and morphological evolution of collagen induced arthritis in mice.
Methods:
Mice with collagen induced arthritis were treated with BN 50730 (0.3, 1, 3 mg/kg) or vehicle (0.1% Tween-20 in saline) once a day, from 3 days before the induction of the arthritis to 70 days after. Disease evolution was followed daily by inspection of inflammatory signs and measurement of the knee joint diameter on Days 0, 40, and 70. At the end of the treatment period, the morphological evaluation of the synovial membrane, the immunodetection of fibronectin, and the content of cartilage proteoglycans were studied.
Results:
On Day 40, mice receiving the highest dose of BN 50730 (3 mg/kg) showed a reduction in the knee joint diameter in comparison with untreated (2.1 +/- 0.2 vs 2.8 +/- 0.4 mm, p < 0.01). On Day 70, animals receiving 1 and 3 mg/kg had a normal knee diameter, while it remained enlarged in the untreated ones. In BN 50730 treated mice (3 mg/kg) we also observed a significant reduction of the inflammation score (0.1 +/- 0.1 vs 2.5 +/- 0.2 in the untreated) and deposition of fibronectin. Depletion of cartilage proteoglycans was also reversed with BN 50730.
Conclusion:
The beneficial effects in this model of joint injury after administration of the PAF antagonist BN 50730 suggest that PAF could be implicated in the pathogenesis of chronic arthritis.
Insights
The PAF receptor antagonist BN 50730 effectively reduced joint swelling and inflammation in a mouse model of chronic arthritis. This suggests platelet-activating factor (PAF) plays a role in arthritis development.
Area of Science:
- Rheumatology and Immunology
- Pharmacology and Drug Discovery
Background:
- Collagen-induced arthritis (CIA) in mice is a widely used model for studying rheumatoid arthritis pathogenesis.
- Platelet-activating factor (PAF) is a potent lipid mediator implicated in inflammatory and immune responses.
Discussion:
- BN 50730, a PAF receptor antagonist, demonstrated significant therapeutic effects in CIA mice.
- Treatment with BN 50730 reduced joint diameter, inflammation scores, and fibronectin deposition.
Key Insights:
- BN 50730 administration reversed cartilage proteoglycan depletion, a hallmark of joint damage.
- The study highlights the critical role of PAF in the progression of chronic arthritis.
Outlook:
- These findings support further investigation of PAF antagonists as potential treatments for human rheumatoid arthritis.
- Targeting the PAF pathway may offer a novel therapeutic strategy for chronic inflammatory joint diseases.